All NewsPractice Management
All VideosExpert InterviewsPodcastsMedical World NewsViewpointsInsightsCase Based Roundtable SeriesCase StudiesCase of the QuarterPractice OwnershipRapid ReadoutWhat’s Your WhEYE?
Conference CoverageConference ListingConference Recaps
Blog
Digital EditionSupplements And Featured PublicationsiTech
Partners
Job BoardSponsored
SubscribeCE
AMD
Allergy
Blepharitis
COVID-19
Cataract
Comanagement
Comprehensive Eye Exams
Conjunctivitis
Contact Lenses
Cornea
DME
Diabetic Eye Disease
Dry Eye
Geographic Atrophy
Glasses
Glaucoma
LASIK
Lens Technology
Lid and Lash
Myopia
Nutrition
OCT
Ocular Surface Disease
Optic Relief
Patient Care
Pediatrics
Presbyopia
Ptosis
Refractive Surgery
Retina
Technology
Therapeutic Cataract & Refractive
Spotlight -
  • Geographic Atrophy
  • Myopia
EyeCare Network
  • Ophthalmology Times

  • Modern Retina

  • Optometry Times

  • Ophthalmology Times Europe

AMD
Allergy
Blepharitis
COVID-19
Cataract
Comanagement
Comprehensive Eye Exams
Conjunctivitis
Contact Lenses
Cornea
DME
Diabetic Eye Disease
Dry Eye
Geographic Atrophy
Glasses
Glaucoma
LASIK
Lens Technology
Lid and Lash
Myopia
Nutrition
OCT
Ocular Surface Disease
Optic Relief
Patient Care
Pediatrics
Presbyopia
Ptosis
Refractive Surgery
Retina
Technology
Therapeutic Cataract & Refractive
EyeCare Network
  • Ophthalmology Times

  • Modern Retina

  • Optometry Times

  • Ophthalmology Times Europe

    • Blog
    • Partners
    • Subscribe
    • CE
Advertisement

New technology will allow roadside simulation for research on cannabis use and driving

December 23, 2022
By Denise A. Valenti, OD, FAAO
Kassi Filkins, Editor
Video
Conference|American Academy of Optometry

Denise A. Valenti, OD, FAAO, gives key takeaways from her AAOpt 2022 discussion on the impact of marijuana use and driving.

Video Player is loading.
Current Time 0:00
/
Duration 1:54
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -1:54
 
1x
    • Chapters
    • descriptions off, selected
    • captions settings, opens captions settings dialog
    • captions off, selected
    • en (Main), selected

    This is a modal window.

    Beginning of dialog window. Escape will cancel and close the window.

    Text
    Background
    Window
    Font Size
    Text Edge Style
    Font Family

    End of dialog window.

    This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

    Denise A. Valenti, OD, FAAO, CEO and owner of IMMAD (Impairment Measurement Marijuana and Driving), shares an update on her company's research during the 2022 American Academy of Optometry meeting held in San Diego.

    Editor's note: This transcript has been edited for clarity.

    Hi, I'm Dr. Denise Valenti. I am the owner of IMMAD (Impairment Measurement Marijuana and Driving), and I'm so pleased to be at this meeting. The Academy has recognized the importance of education for primary care clinicians and clinicians on cannabis.

    I attended an incredible lecture by Dr. Ng from Southern California College of Optometry—a comprehensive lecture on basic information and cannabis. I'm excited to be presenting a lecture on driving and cannabis. This is in total conjunction with the area my company researches.

    We are excited that we were recently awarded a grant from the federal government—the National Institutes on Justice—to measure a developing technology that looks at retinal function to determine if you're too high to drive.

    Part of this project will be in developing a standardized, closed-road, real-car test system to detect impairment functions specific to driving. Now part of this is we're going to be working with a robotic technology that is very novel, we are going to be adapting the National Football League MVP practice dummy. We are turning it into a multi-directional robotic to use roadside as a simulation of our pedestrian.

    So we are so excited that we have this opportunity to advance our research, but again, we're happy that the Academy recognizes how important it is for clinicians to know about cannabis/marijuana use and the impact on their patient.

    Newsletter

    Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

    Subscribe Now!
    Recent Videos
    Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
    CCS 2025: Taking a contemporary approach to dry eye disease with Dr Mitch Ibach
    Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.
    A sneak peek into the Collaborative Care Symposium 2025 with Steven Greenstein, MD
    Dr Julie Poteet reports on patient-reported outcomes using lipid-containing artificial tear
    ARVO 2025: Dr Julie Poteet reviews patient-reported outcomes following use of Blink Triple Care
    Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
    ARVO 2025: Lens thickness as a significant biomarker for accommodation in presbyopia
    Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
    ARVO 2025: OCT-based marker for accommodative effort in presbyopes
    Karl Stonecipher ASCRS 2025
    Q&A with Karl Stonecipher, MD, on outcomes of LASIK using the Teneo platform to correct high myopia
    AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
    Predicting presbyopia reading ADD and progression with AI and machine learning algorithm
    Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
    CIME 2025: What you missed in presbyopia tips, tricks, and updates
    At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
    ARVO 2025: Rethinking centile growth curves in myopia management with Mark Bullimore, MCOptom, PhD
    Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
    CIME 2025: Luke Lindsell, OD, MD, on bridging innovation and practical care in retinal disease
    Related Content
    Advertisement
    Four hands putting together puzzle pieces Image credit: AdobeStock/Johnstocker

    Pangaea Data and Topcon Healthcare announce strategic investment

    Jordana Joy, Associate Editor
    May 30th 2025
    Article
    New Opportunities in Topical Glaucoma Management

    New Opportunities in Topical Glaucoma Management

    Mitch Ibach, OD, FAAO;Jessica Steen, OD, FAAO
    January 31st 2025
    Podcast
    Collaborative Care Symposium cochairs Gelles and Greenstein preview the 2025 meeting

    Bridging disciplines and elevating care: A Q&A with John Gelles, OD, and Steven Greenstein, MD

    John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA;Steven A. Greenstein, MD;Emily Kaiser Maharjan, Assistant Managing Editor
    May 28th 2025
    Article
    You and Eye: Vision training research in eSports - with Tiffany Tsoi, OD, FAAO

    You and Eye: Vision training research in eSports - with Tiffany Tsoi, OD, FAAO

    Miriam Korik, OD;Tiffany Tsoi, OD;Emily Kaiser Maharjan, Assistant Managing Editor
    December 4th 2024
    Podcast
    Clinical trial graphic Image credit: AdobeStock/photon_photo

    Disparities found in uveitis clinical trials access by researchers

    Jordana Joy, Associate Editor
    May 27th 2025
    Article
    iRORA conversion found using fundus autofluorescence - Image credit: ©K Davis/peopleimages.com—stock.adobe.com

    iRORA phenotypes characterized using fundus autofluorescence

    Lynda Charters
    May 23rd 2025
    Article
    Related Content
    Conference
    |
    Clinical
    |
    Patient Care
    |
    Retina
    |
    Technology
    |
    American Academy of Optometry
    Advertisement
    Four hands putting together puzzle pieces Image credit: AdobeStock/Johnstocker

    Pangaea Data and Topcon Healthcare announce strategic investment

    Jordana Joy, Associate Editor
    May 30th 2025
    Article
    New Opportunities in Topical Glaucoma Management

    New Opportunities in Topical Glaucoma Management

    Mitch Ibach, OD, FAAO;Jessica Steen, OD, FAAO
    January 31st 2025
    Podcast
    Collaborative Care Symposium cochairs Gelles and Greenstein preview the 2025 meeting

    Bridging disciplines and elevating care: A Q&A with John Gelles, OD, and Steven Greenstein, MD

    John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA;Steven A. Greenstein, MD;Emily Kaiser Maharjan, Assistant Managing Editor
    May 28th 2025
    Article
    You and Eye: Vision training research in eSports - with Tiffany Tsoi, OD, FAAO

    You and Eye: Vision training research in eSports - with Tiffany Tsoi, OD, FAAO

    Miriam Korik, OD;Tiffany Tsoi, OD;Emily Kaiser Maharjan, Assistant Managing Editor
    December 4th 2024
    Podcast
    Clinical trial graphic Image credit: AdobeStock/photon_photo

    Disparities found in uveitis clinical trials access by researchers

    Jordana Joy, Associate Editor
    May 27th 2025
    Article
    iRORA conversion found using fundus autofluorescence - Image credit: ©K Davis/peopleimages.com—stock.adobe.com

    iRORA phenotypes characterized using fundus autofluorescence

    Lynda Charters
    May 23rd 2025
    Article
    Advertisement
    Recent Content
    Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.

    CCS 2025: Taking a contemporary approach to dry eye disease with Dr Mitch Ibach

    Swept source anterior segment OCT aids in early diagnosis of childhood glaucoma. - Image credit: ©Serhii—stock.adobe.com

    Swept-source anterior segment-OCT aids in early diagnosis of childhood glaucoma

    Four hands putting together puzzle pieces Image credit: AdobeStock/Johnstocker

    Pangaea Data and Topcon Healthcare announce strategic investment

    Closeup of dry eye before and after treatment. Image credit: AdobeStock/AlessandroGrandini

    Iolyx Therapeutics releases phase 2 results for ILYX-002 in autoimmune-associated dry eye disease

    View More Recent Content
    Advertisement
    Advertisement
    x
    Advertise
    About Us
    Editorial
    Contact Us
    Job Board
    Terms & Conditions
    Privacy
    Do not sell my Information
    Contact Info

    2 Commerce Drive
    Cranbury, NJ 08512

    609-716-7777

    Download on Apple
    © 2025 MJH Life Sciences

    All rights reserved.